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Abstract
Background: Recent studies have demonstrated the consistently high diagnostic and prognostic value of
dobutamine stress cardiovascular magnetic resonance (DCMR). The value of DCMR for clinical decision making still
needs to be defined. Hence, the purpose of this study was to assess the utility of DCMR regarding clinical
management of patients with suspected and known coronary artery disease (CAD) in a routine setting.
Methods and Results: We prospectively performed a standard DCMR examination in 1532 consecutive patients
with suspected and known CAD. Patients were stratified according to the results of DCMR: DCMR-positive patients
were recommended to undergo invasive coronary angiography and DCMR-negative patients received optimal
medical treatment. Of 609 (40%) DCMR-positive patients coronary angiography was performed in 478 (78%) within
90 days. In 409 of these patients significant coronary stenoses ≥50% were present (positive predictive value 86%).
Of 923 (60%) DCMR-negative patients 833 (90%) received optimal medical therapy. During a mean follow-up
period of 2.1 ± 0.8 years (median: 2.1 years, interquartile range 1.5 to 2.7 years) 8 DCMR-negative patients (0.96%)
sustained a cardiac event.
In 131 DCMR-positive patients who did not undergo invasive angiography, 20 patients (15%) suffered cardiac
events. In 90 DCMR-negative patients (10%) invasive angiography was performed within 2 years (range 0.01 to 2.0
years) with 56 patients having coronary stenoses ≥50%.
Conclusion: In a routine setting DCMR proved a useful arbiter for clinical decision making and exhibited high
utility for stratification and clinical management of patients with suspected and known CAD.
Background
Physicians commonly have to determine the need for
invasive angiography in patients with suspected or
known coronary artery disease (CAD). Current
guidelines and recent studies have emphasized the
importance of non-invasive stress testing for the detec-
tion of myocardial ischemic reactions prior to invasive
angiography [1-3]. Dobutamine stress cardiovascular
magnetic resonance (DCMR) is well established for the
evaluation of patients with suspected and known CAD
[4-9]. Apart from merely detecting stress inducible myo-
cardial ischemia, there is growing evidence supporting
the value of DCMR to assess cardiac prognosis [10,11].
As for other imaging modalities, patients with an inter-
mediate pretest probability for the presence of CAD
benefit most from DCMR [12]. However, data on the
usefulness of DCMR testing to direct patient treatment
regarding medical versus invasive strategies has not
been reported yet. Hence, we sought to evaluate the
value of DCMR as the sole clinical decision maker in a
large unselected patient population and determined its
utility for clinical management of patients with
suspected and known CAD.* Correspondence: gebker@dhzb.de1German Heart Institute Berlin, Germany
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Methods
Patient population
The study was conducted in accordance with the
Institutional Review Board at the Charité University
School of Medicine and written informed consent was
given by all patients. Between November 2005 and July
2008, 1699 patients were examined prospectively for the
evaluation of chest pain syndromes or dyspnea. Patients
were eligible if they had suspected or known CAD
including patients with prior interventional or surgical
revascularization. Patients with contraindications to
either CMR (non-compatible biometallic implants) or
dobutamine (e.g. unstable angina, myocarditis, endocar-
ditis) and patients with atrial fibrillation were not con-
sidered. All patients were instructed to refrain from
beta-blockers 24 hours prior to the MR study. Medical
history was obtained immediately before DCMR. Clini-
cal variables were defined according to the Framingham
Risk Score assessment [13].
DCMR
As previously described DCMR was performed in the
supine position on a 1.5 Tesla Intera CV system (Philips
Medical Systems, Best, The Netherlands) [7]. Cardiac
standard geometries (three short axis views and a four-,
two- and three-chamber view) were acquired at rest and
during dobutamine/atropine stress to achieve target
heart rate, defined as 85% of the maximum predicted
heart rate: (220-age) × 0.85. Termination criteria were
as previously published [14]. Total examination time
was ≈ 30 minutes.
MR Sequences
For cine imaging, balanced steady-state free precession
(bSSFP) sequences with retrospective gating (50 phases
per cardiac cycle) were used during an end-expiratory
breath hold [repetition time (TR), 3.4 ms; echo time
(TE), 1.7 ms; flip angle, 60°]. In-plane spatial resolution
was 1.8 × 1.8 mm with a slice thickness of 8 mm.
Image analysis
The study sought to address the impact of DCMR on
clinical management in routine practice, so the results of
each study were interpreted at the time of the original
examination by cardiologists trained in DCMR. All image
analysis was performed on a commercially available View
Forum station (Philips Medical Systems, Best, The
Netherlands). Segmental analysis of wall motion was per-
formed using a synchronized quad-screen image display
and applying a standard 17-segment scoring system
during each stage of the protocol (1 = normal, 2 = hypo-
kinetic, 3 = akinetic, or 4 = dyskinetic) [15]. A positive
DCMR (DCMR-pos) was defined as a stress inducible
wall motion abnormality (IWMA) in ≥ 1 segment;
a biphasic response was also considered to indicate a
positive DCMR. A negative DCMR (DCMR-neg) was
defined as the absence of a stress inducible wall motion
abnormality. Left ventricular function was determined
using a combined triplane model [16]. DCMR results
were made available to the referring physician immedi-
ately after finishing the examination using a standardized
reporting sheet.
Follow-up
Outcome data were collected from a standardized
mailed questionnaire, telephone interview with the
patient or a close relative and hospital chart review; all
reported clinical events were confirmed by contact with
the patient’s general practitioner or the treating hospital.
Survival information was obtained from the Department
of National Registration for patients lost on first contact.
Cardiac death and nonfatal myocardial infarction were
registered as cardiac events. Cardiac death was defined
as death in the presence of acute coronary syndrome,
fatal arrhythmia, refractory cardiac failure or sudden
unexpected death; nonfatal myocardial infarction was
defined by angina and an increase in cardiac-specific
enzymes and/or development of new ECG changes (i.e.,
transient ST-segment elevation). In the case of 2 simul-
taneous events the worst event was chosen (cardiac
death > myocardial infarction). We documented the rea-
sons to perform invasive coronary angiography despite a
negative DCMR during the 2 years following the exami-
nation with the period being chosen based on data from
a previous prognosis study [11]. Conversely, the reasons
not to perform invasive angiography within 90 days in
patients with a positive DCMR were also noted. Patients
who underwent coronary artery bypass grafting or per-
cutaneous coronary intervention were censored at the
time of revascularization.
Coronary Angiography
Invasive coronary angiography was performed at the dis-
cretion of the referring physicians. The angiograms were
evaluated visually for the presence of significant stenoses
(i.e. ≥ 50% luminal diameter reduction) in the three
large epicardial coronary arteries and their major
branches (i.e. vessel diameter ≥ 2.0 mm) by highly
experienced invasive cardiologists.
Statistical analysis
Statistical analysis was performed using the SPSS
software package release 15.0.1 (Chicago, USA). For all
continuous parameters, data are expressed as mean ±
standard deviation. Additionally, follow-up duration is
presented as median with lower and upper quartiles.
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The normality of the distributions was tested with the
Kolmogorov-Smirnov test. Comparisons between two
groups of continuous data were made with unpaired
Student t or Mann-Whitney U test where appropriate.
Discrete data was analyzed with the chi-square and
Fisher’s exact test when appropriate. Sensitivity was cal-
culated according to standard definitions. The Kaplan-
Meier method was used to construct plots depicting
clinical events as a function of follow-up duration, and
curves were compared using the log-rank test. Statistical
tests were two-tailed; significance was reached if p <
0.05.
Results
Patient Characteristics
Of the initial 1699 patients, 124 were excluded due to
claustrophobia (n = 46, 2.7%), technical problems
(e.g. ECG mistriggering and insufficient image quality)
(n = 17, 1%) and limiting side effects during the admin-
istration of dobutamine/atropine with premature termi-
nation of the MR examination (n = 61, 3.6%), including
36 patients with severe chest pain and/or dyspnea, 20
with supraventricular tachycardia, 3 with severe increase
in blood pressure > 240/120 mmHg and 2 with non-sus-
tained ventricular tachycardia. None of the patients died
or suffered from a myocardial infarction related to
DCMR testing. Of the remaining 1575 patients, 43 were
lost to follow-up (2.7%). Thus, final analysis was per-
formed on 1532 patients. During DCMR target heart
rate was achieved in 1442 patients (94%). Tables 1, 2, 3
and 4 provide the clinical baseline characteristics and
hemodynamic data of the final patient population
according to the result of DCMR, respectively.
Outcomes
A summary of the outcome data is given in Figure 1.
Table 5 provides a summary of events according to
DCMR results. In 609 DCMR-pos patients elective inva-
sive angiography was recommended. In 478 out of these
609 patients (78%) invasive angiography was performed
within 90 days with 409 patients demonstrating hemo-
dynamically relevant coronary stenoses ≥50% (positive
predictive value 86%), see Figure 2 for an example of a
DCMR-pos patient. Coronary revascularization was per-
formed in 365 patients. In 69 DCMR-pos patients who
underwent invasive angiography without demonstrating
coronary stenoses 2 events occurred (event rate 2.9%);
these patients had known CAD with moderately reduced
LV-function. In 131 patients who did not undergo
elective invasive angiography within 90 days 20 events
(4 deaths and 16 myocardial infarctions) occurred (event
rate 15.3%). The reasons not to perform elective invasive
angiography despite a positive DCMR were: patient’s
refusal (n = 36, 27%; 5 events), few symptoms (n = 20,
15%; 1 event), limited amount of ischemia(n = 16, 12%;
mean number of segments with IWMA 1.2 ± 0.4; 1
event), limited amenability to revascularization proce-
dures (e.g. in known chronic coronary vessel occlusion
(n = 17, 13%; 3 events)), early occurrence of an event
within 90 days (n = 9, 7%) and remained unknown in
33 cases (25%; 1 event).
In 923 DCMR-neg patients medical treatment was
recommended. No elective invasive angiography was
performed within 2 years in 833 out of these 923
patients (90%). Mean follow-up period was 2.1 ± 0.8
years (median: 2.1 years, interquartile range 1.5 to 2.7
years). In this patient subgroup 8 events (3 deaths, 5
myocardial infarctions) occurred (event rate 0.96%;
Figure 3). Six out of these 8 patients (75%) had known
CAD with prior sustained myocardial infarctions; the
mean time to an event was 434 ± 219 days. In 90
DCMR-neg patients elective angiography was performed
(10%) with a mean time to invasive angiography of 7 ±
7 months (median: 5 months, interquartile range 0.03 -
13 months), with 56 patients demonstrating coronary
stenoses ≥50%. Out of these patients, 34 had single ves-
sel CAD, 16 had double vessel CAD and 6 had triple
vessel CAD, no patient had relevant left main disease.
Coronary revascularization was performed in 46
patients. In the remaining 34 patients without coronary
stenoses no events occurred during follow up. The
reasons to perform elective invasive angiography within
Table 1 DCMR-positive vs.DCMR-negative patients
DCMR-pos
patients
DCMR-neg
patients
N = 609 N = 923 p†
Clinical characteristics
Age [years] 64 ± 9 62 ± 11 0.04
Male, % 74 63 <0.001
Body mass index [kg/
m2]
28 ± 4 27 ± 4 <0.001
LVEF 56 ± 9 58 ± 6 <0.001
Hypertension, % 79 70 <0.001
Hyperlipidemia, % 75 59 <0.001
Diabetes mellitus, % 28 19 <0.001
Smoking, % 30 31 0.58
Family history, % 25 33 <0.001
Framingham risk score 16 ± 11 15 ± 11 0.04
Known CAD, % 68 35 <0.001
Prior myocardial
infarction, %
35 29 0.03
Prior PCI, % 57 28 <0.001
Prior CABG, % 26 12 <0.001
Values are expressed as mean ± SD or %, †DCMR-pos patients vs. DCMR-neg
patients
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2 years of a negative DCMR were: persisting complaints
of angina/dyspnea (n = 46; 51%), pathologic findings on
another stress test performed within 2 years (n = 21;
23%) or other clinical reasons (e.g. coronary angiography
during an electrophysiologic study (n = 23; 26%)).
Table 6 demonstrates cumulative survival rates in
patients stratified according to DCMR test results at 1-,
2- and 3-year follow-up intervals; the 3-year event-free
survival was 98.5% for patients with negative DCMR
and 94% for those with abnormal DCMR.
Segmental extent of ischemia vs. event rate
The mean number of segments with IWMA in the overall
population was 1.18 ± 1.73. The number of segments with
IWMA in patients with cardiac events was significantly
higher compared to those without events (2.1 ± 1.8 vs. 1.2
± 1.7, respectively; p = 0.003). In particular, patients with
an early event occurring <90 days after DCMR showed a
significantly higher number of segments with IWMA than
those with a late event occurring >90 days after DCMR
(3.42 ± 1.62 vs. 1.26 ± 1.41; p = 0.001).
Discussion
The present study addressed the impact of DCMR on
clinical management in a large unselected patient popu-
lation with chest pain syndromes. The main findings are
1) DCMR is applicable in a clinical routine setting with
a high success rate and few stressor related complica-
tions during a reasonably short examination time of less
than 30 minutes, 2) DCMR proved useful as an arbiter
for clinical decision making with regard to invasive ver-
sus medical treatment in patients with suspected and
known CAD, 3) the positive predictive value of DCMR
to detect coronary luminal narrowing >50% is high, 4) a
positive DCMR is a powerful predictor of future cardiac
events, and 5) a negative DCMR test result infers a low
risk for subsequent cardiac events (about 1% in the two
years after stress testing).
Table 2 Clinical data in DCMR-pos patients
DCMR-pos patients Patients with invasive angiography
invasive angio no invasive angio stenosis* no stenosis*
n = 478 n = 131 p† n = 409 n = 69 p‡
Clinical characteristics
Age [years] 64 ± 9 66 ± 9 0.03 64 ± 9 60 ± 10 0.001
Male, % 73 78 0.26 78 45 <0.001
Body mass index [kg/m2] 28 ± 4 27 ± 3 0.007 28 ± 4 28 ± 4 0.63
LVEF 56 ± 8 54 ± 11 0.61 55 ± 8 59 ± 6 <0.001
Hypertension, % 80 76 0.26 83 65 0.002
Hyperlipidemia, % 76 74 0.7 79 54 <0.001
Diabetes mellitus, % 29 24 0.31 30 20 0.11
Smoking, % 30 30 0.9 30 32 0.78
Family history, % 23 30 0.11 22 30 0.12
Framingham risk score 16 ± 11 18 ± 12 0.26 17 ± 11 12 ± 7 0.002
Known CAD, % 68 65 0.45 75 29 <0.001
Prior myocardial infarction, % 33 41 0.12 33 36 0.55
Prior PCI, % 58 53 0.34 64 26 <0.001
Prior CABG, % 26 27 0.9 30 6 <0.001
Medication, %
Aspirin 93 95 0.51 98 56 <0.001
Betablocker 88 89 0.68 92 58 <0.001
ACE inhibitor 70 66 0.47 72 54 0.009
Angiotensin receptor blocker 26 30 0.36 25 29 0.61
Calcium channel blocker 32 30 0.74 31 39 0.34
Statin 92 90 0.64 96 58 <0.001
Diuretic 43 41 0.8 44 37 0.37
Values are expressed as mean ± SD or %, *luminal diameter reduction ≥50% on invasive coronary angiography, †DCMR-pos patients with vs. without invasive
coronary angiography,‡DCMR-pos patients with vs. without coronary stenosis
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One of the most important clinical questions that
non-invasive stress testing has to address is whether
patients should be advised to undergo invasive angiogra-
phy or to continue with medical treatment. As a result
of major advances in imaging technology, several
diagnostic strategies have become available over the past
decades. Although exercise electrocardiography is advo-
cated as a first-line procedure [1], sensitivity may be as
low as 45 percent and many patients cannot exercise
sufficiently due to poor functional status [17]. In order
Table 3 Clinical data in DCMR-neg patients
DCMR-neg patients Patients without invasive angiography
no invasive angio invasive angio no event event
n = 833 n = 90 p† n = 825 n = 8 p‡
Clinical characteristics
Age [years] 62 ± 11 64 ± 11 0.27 62 ± 11 59 ± 10 0.28
Male, % 62 72 0.06 62 71 0.61
Body mass index [kg/m2] 27 ± 4 27 ± 4 0.77 27 ± 4 28 ± 6 0.29
LVEF 58 ± 6 58 ± 8 0.31 58 ± 6 53 ± 14 0.76
Hypertension, % 70 76 0.26 70 86 0.36
Hyperlipidemia, % 57 71 0.01 57 86 0.13
Diabetes mellitus, % 19 22 0.39 18 29 0.49
Smoking, % 30 41 0.03 30 29 0.93
Family history, % 34 30 0.49 34 14 0.28
Framingham risk score 15 ± 11 16 ± 11 0.56 15 ± 11 18 ± 9 0.7
Known CAD, % 32 58 <0.001 32 57 0.15
Prior myocardial infarction, % 22 30 0.11 30 71 0.03
Prior PCI, % 25 52 <0.001 25 43 0.38
Prior CABG, % 10 22 0.001 10 29 0.16
Medication, %
Aspirin 60 87 <0.001 60 86 0.25
Betablocker 62 76 0.01 61 100 0.04
ACE inhibitor 48 67 0.001 48 57 0.71
Angiotensin receptor blocker 25 20 0.4 25 14 0.53
Calcium channel blocker 21 27 0.28 21 14 0.65
Statin 57 87 <0.001 56 71 0.43
Diuretic 32 46 0.02 32 29 0.83
Values are expressed as mean ± SD or %, †DCMR-pos patients with vs. without invasive coronary angiography, ‡DCMR-pos patients with vs. without coronary
stenosis
Table 4 Hemodynamic data
All patients DCMR-pos DCMR-neg
n = 1532 n = 609 n = 923 p†
Hemodynamic data
Dobutamine dose (μg/kg/min) 35 ± 8 35 ± 8 35 ± 8 0.5
Atropine dose (mg) 0.25 ± 0.35 0.26 ± 0.36 0.24 ± 0.35 0.27
Resting HR, beats/minute 73 ± 13 72 ± 14 73 ± 13 0.008
Peak HR, beats/minute 139 ± 10 138 ± 11 140 ± 10 <0.001
Target HR achieved, % 94 91 97 <0.001
Resting SBP, mmHg 132 ± 22 133 ± 23 132 ± 22 0.68
Peak SBP, mmHg 141 ± 30 141 ± 32 141 ± 29 0.83
Resting Rate Pressure Product 9691 ± 2748 9607 ± 2829 9747 ± 2695 0.12
Peak Rate Pressure Product 18759 ± 4275 18893 ± 4351 18667 ± 4236 0.31
Values are expressed as mean ± SD or %, †DCMR-pos vs. DCMR-neg patients
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to determine a patient’s most appropriate management
multiple tests may be conducted and frequently yield
conflicting results. Thus, in a large number of indivi-
duals a single imaging test in conjunction with pharma-
cological stress as the initial strategy may be the most
effective approach in patient care. Whereas echocardio-
graphy and radionuclide imaging have been evaluated
extensively, data on CMR based management strategies
are scarce. DCMR has matured into a technically robust
method with similarly high values for sensitivity and
specificity of ≈ 85% for the detection of myocardial
ischemic reactions in the presence of obstructive
coronary lesions [12] and has been shown to provide
relevant prognostic information [10,11,18]. Previous stu-
dies focused on the prognostic value of DCMR in low/
intermediate versus high risk patient groups as defined
by conventional cardiovascular risk factors and reported
a relative merit of stress magnetic resonance testing
[19]. The design of the present study, however, was
unique in that it established the utility of DCMR testing
as the sole clinical decision maker in a routine clinical
setting: our study attributed DCMR testing an active
role in clinical decision making with treatment directed
either to a medical or invasive strategy. Consequently,
while corroborating the usefulness of DCMR testing,
our data closely reflects clinical reality in a tertiary care
center setting and as such will be applicable to a similar
clinical scenario.
The overall safety profile and frequency of adverse
events of DCMR observed in our study are in agreement
with previous reports using CMR and other well estab-
lished methodologies using high dose dobutamine-atro-
pine stress protocols [9,20]. Results of DCMR were
DCMR
(n=1532)
DCMR-pos
(n=609)
DCMR-neg
(n=923)
Invasive angio*
(n=478)
No invasive angio*
(n=131)
Stenosis >50%: 409
No stenosis: 69
20 events
1 event
Invasive angio**
(n=90)
No invasive angio**
(n=833)
Stenosis >50%: 56
No stenosis: 34
8 events
no events
No revascularization: 44 no events
1 event
*within 90 days, **within 2 years
Figure 1 Summarizes the outcome of our patient population according to the results of DCMR.
Table 5 Summary of events
All DCMR-pos DCMR-neg
n = 1532 n = 609 n = 923 p†
Events (%)
Cardiac death 8 (0.5) 5 (0.8) 3 (0.3) 0.28
Myocardial infarction 22 (1.5) 17 (3.0) 5 (0.5) <0.001
Values are expressed as n (%), †DCMR-pos vs. DCMR-neg patients
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communicated in a timely and definitive manner to the
referring physician so that they formed the basis for
subsequent clinical decision making.
In our study most patients with a positive DCMR
underwent invasive angiography with the intention to
perform revascularization. Compared to prior results
regarding the diagnostic accuracy of DCMR, this study
confirms the high predictive value for the detection of
angiographically relevant obstructive coronary stenoses
in a population with known or suspected CAD [5,6].
DCMR-positive patients who did not undergo invasive
angiography within 90 days frequently sustained hard
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Figure 2 DCMR in a 56 year old man with exertional dyspnoea and atypical chest pain. He had arterial hypertension and was an active
smoker without a prior history of CAD. He was referred for DCMR after a normal exercise ECG and insufficient image quality for a stress
echocardiography. DCMR (top and middle) revealed a stress inducible wall motion abnormality of the apical and mid-ventricular anteroseptal
segments (white arrows). Invasive angiography (bottom row) demonstrated high grade stenosis of the LAD (white arrow) and intermediate
stenoses of the LCX and distal RCA (white arrowheads).
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cardiac events. Interestingly, the number of patients who
sustained early events was relatively high compared to
results of the recently published COURAGE and BARI-
2D trials which compared invasive vs. conservative man-
agement of stable CAD [21,22]. However, there are cer-
tain methodological differences between these trials and
our study. First, all patients in the above mentioned
trials had to have angiographically proven significant
coronary stenosis as an inclusion criterion. In the pre-
sent study, however, patients were classified with regard
to inducible ischemia on the myocardial level. Thus,
generalization from these trials to the present patient
population is limited. Second, subgroup analyses from
COURAGE and BARI-2D showed that outcome is
worse with complex CAD and high extent of inducible
ischaemia, and that early revascularisation in addition to
optimal medical therapy was better than optimal phar-
macological therapy alone [3,23]. Since early revasculari-
zation is likely to improve outcome in these high-risk
patients, the pivotal role of cardiac imaging as an arbiter
in clinical decision making is further corroborated. In
our study patients with early events had a significantly
greater extent of ischemia suggesting that an early refer-
ral to invasive angiography may be advisable in this
patient group. Prior studies using SPECT [24] and echo-
cardiography [25] demonstrated that the extent and
severity of stress inducible ischemia is associated with a
worse outcome, however, similar data using DCMR test-
ing is still limited.
The vast majority of DCMR-negative patients in our
study did not undergo invasive angiography during fol-
low-up time. Similar to SPECT imaging and stress echo-
cardiography, a normal DCMR has generally been
associated with a hard annual cardiac event rate of ≈ 1%
[10,11,26,27]. Data from randomized trials proved that
DCMR-neg
DCMR-pos
P<0.001 
0.6
0.7
0.8
0.9
1.0
0.5
#at risk
DCMR-neg
DCMR-pos
923
609
136
35
493
109
835
189
Figure 3 Kaplan-Meier curves illustrating the time-to-event distributions of cardiac events stratified according to the results of DCMR
testing. Differences between the curves are statistically significant (P<0.001 by log-rank test).
Table 6 Cumulative Survival Rates at Follow up Intervals
Cumulative Survival Rates at Follow up Intervals,
%
Result of DCMR 1y 2y 3y
DCMR-negative 99,5 99,2 98,5
DCMR-positive 96,1 95,1 94,0
log Rank <0.001
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the low rate of cardiac events in patients with negative
stress examinations cannot be improved by revasculari-
zation as indicated in current guidelines [1,28]. These
patients can be safely treated initially with medical ther-
apy and should only be investigated further if their
symptoms cannot be controlled. The impetus for
DCMR-driven management has been data from a pre-
viously published study dealing with the prognostic
value of DCMR and demonstrating a warranty period of
two years in case of a negative DCMR test result [11].
In our study 10 percent of the patients with a negative
DCMR were subsequently referred for invasive angiogra-
phy largely owing to recurrent anginal symptoms. In 52
percent revascularization was performed indicating that
these patients may have been misclassified as DCMR-
neg. The overall “false-negative” rate in our study, how-
ever, was low. Previous studies using stress echocardio-
graphy have shown that chest pain in the absence of
identifiable wall motion abnormalities represents an
independent predictor of future cardiac events and
should be considered in the interpretation of a normal
examination [29]. In addition, it most likely also reflects
clinical practice since physicians facing a patient with
uncontrolled symptoms are more likely to refer for inva-
sive angiography based on their clinical judgment
regardless of the results of prior non-invasive testing.
Furthermore, the sensitivity of stress inducible wall
motion abnormalities as a marker of ischemia is known
to be slightly lower compared to myocardial perfusion
imaging techniques. Thus, the addition of perfusion
imaging during high dose dobutamine may be helpful in
detecting patients with ischemia [4]. Nevertheless, all
DCMR-neg patients who underwent invasive angiogra-
phy without revascularization did not sustain any hard
cardiac events supporting the high negative predictive
value of the test.
Limitations
Delayed enhancement (DE) images were not acquired
for the purpose of this study. The presence and extent
of DE has already been demonstrated to carry indepen-
dent prognostic value [30,31]. Recently, the combination
of CMR vasodilator stress myocardial perfusion and DE
was shown to provide complementary prognostic impli-
cation for cardiac events [32]. Thus, with regard to
prognostication the addition of DE to DCMR may be
beneficial in certain patient populations. Visual analysis
of invasive angiography by experienced interventional
cardiologists was used to determine the degree of coron-
ary luminal narrowing. Quantitative coronary angiogra-
phy (QCA) is often used as a reference standard in
clinical trials, but its usage during routine coronary
angiography is rather limited though it may be per-
formed to assist planning of a revascularization
procedure. The aim of the present study, however, was
to define the role of DCMR testing within a widely seen
clinical scenario.
Conclusions
In our study we demonstrated that a DCMR based man-
agement strategy can be used as a reliable gatekeeper to
invasive procedures or to substantiate the decision to
proceed with medical treatment. Thus, DCMR provides
a directive for appropriate and profound clinical man-
agement of patients with suspected and known CAD.
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